+

WO1999038472A2 - Composition de gel de vasodilatation topique et ses methodes d'utilisation et de production - Google Patents

Composition de gel de vasodilatation topique et ses methodes d'utilisation et de production Download PDF

Info

Publication number
WO1999038472A2
WO1999038472A2 PCT/US1999/001830 US9901830W WO9938472A2 WO 1999038472 A2 WO1999038472 A2 WO 1999038472A2 US 9901830 W US9901830 W US 9901830W WO 9938472 A2 WO9938472 A2 WO 9938472A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
nitroglycerin
vasodilatory
gel
Prior art date
Application number
PCT/US1999/001830
Other languages
English (en)
Other versions
WO1999038472A3 (fr
Inventor
Inc. Seatrace Pharmaceuticals
Oscar Hugh Campbell
Original Assignee
Seatrace Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seatrace Pharmaceuticals Inc filed Critical Seatrace Pharmaceuticals Inc
Priority to AU24790/99A priority Critical patent/AU2479099A/en
Publication of WO1999038472A2 publication Critical patent/WO1999038472A2/fr
Publication of WO1999038472A3 publication Critical patent/WO1999038472A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Definitions

  • the present invention relates to the field of pharmacology and, in particular, relates to a vasodilatory gel useful for topical application for the treatment of vascular insufficiency, a method for making the vasodilatory gel, and a method for using the vasodilatory gel for stimulating blood flow, and for the treatment of vascular insufficiency.
  • the present invention includes use of nitroglycerin as the vasodilatory substance in the vasodilatory gel.
  • Vascular insufficiency may be related to a variety of systems including but not limited to the nervous, endocrine, and cardiovascular systems. Vascular insufficiency affects many different functions including sexual arousal and attainment of orgasm. Vascular filling of the erectile tissues of the external genitalia of males and females is a critical component in causing erections of the penis and clitoris. The corpora cavernosa and corpus spongiosum fill with blood during human sexual arousal. In the female, sexual arousal includes increased vascular flow to other structures in the perineum including the bulbs of the vestibule and the labia minora. Proper vascular flow to these structures is an important component of sexual arousal, sexual response, the attainment of penile and clitoral erections, and orgasm.
  • Impotence is a condition of vascular insufficiency in which there is inadequate filling of the erectile tissue of the penis with blood and inadequate maintenance of the blood pressure in the erectile tissue.
  • Impotence is a condition of varied etiology including vascular, neurologic, endocrine, drug, and psychogenic causes. More specifically, peripheral vascular disease, disturbances of the autonomic motor nerves and/or sensory perineal nerves, alcoholism, reproductive steroids, diabetes, arteriosclerosis, hypertension and psychic causes may be involved in the etiology of impotence and female sexual dysfunction (see McConnell et ai, pg. 286-288, and Carr et ai, pg. 289-292, both in Harrison's Principles of Internal Medicine 14th edition, 1998, Fauci et al, eds., McGraw-Hill Inc., New York).
  • anorgasmia As human life expectancy grows, the incidence of peripheral vascular disease, anorgasmia, and impotence in the aging population will increase.
  • the psychological consequences of impotence and anorgasmia include depression, loneliness, feelings of worthlessness, performance anxiety, anxiety about sexual satisfaction of the individual with impotence or anorgasmia, and also anxiety about sexual satisfaction of his or her sexual partner.
  • impotent men seek psychological or psychiatric treatment and are often prescribed medications which may complicate the prognosis for treatment of impotence. Many times these psychological conditions cause additional medical problems that require medical intervention.
  • An effective composition for treating impotence that is easy to apply would decrease the incidence of these negative psychological consequences and their clinical sequelae.
  • animals may also experience difficulties obtaining erections at the appropriate time for reproduction of the species.
  • animals such as horses or cattle bred for superior genetic capabilities, the inability to obtain erections sometimes necessitates the use of electrical stimulators.
  • Animals such as stud horses and stud cattle would benefit from methods and compositions to induce erections that do not require the use of electrical stimulators.
  • Other attempts to treat impotence include injection of papaverine, alprostadil, phentolamine or other drugs into the corpora cavernosa of the penis (Roy et ai, Spinal Cord 35:99-103, 1997). While this technique is somewhat effective, the prospect of repeatedly injecting drugs into the penis is not appealing to many individuals and is associated with increased risk of infection, hematoma formation, and development of scar tissue.
  • Intrauretheral application of vasodilatory substances is a mode of administration that is unappealing and uncomfortable to many men and also cumbersome in the period preceding intercourse.
  • intraurethral administration can irritate the epithelium of the penile urethra and cause infection.
  • Patches containing vasodilatory substances such as nitroglycerin are known in the prior art for the treatment of angina pectoris and other cardiac symptoms. These patches are known by names such as TRANSDERM-NITRO® (CIBA-Geigy Corp.), DEPONIT® (Schwarz-Pharma), NITRO-DUR® (Key Pharmaceuticals, Inc.), and NITRODISC® (Roberts Pharmaceutical Corp.). These products generally contain nitroglycerin in a polymer matrix with lactose, plasticizer, resinous cross-linking agents, silicon dioxide, penetrants such as polyethylene glycol or isopropyl palmitate, adhesive and other substances designed for prolonged time release characteristics.
  • patches are designed for long term treatment and are not configured to fit the penile shaft or to rapidly induce erections. Long term treatment with patches can also result in tolerance to the effects of nitroglycerin. Rubber bands are sometimes employed to maintain contact of the patch with the base of the penis (Roy et al, Spinal Cord 35:99-103, 1997). Due to the design of these patches and the differences in the length and circumference of the flaccid penis, application of such patches is impractical, cumbersome and sometimes impossible.
  • pastes have incorporated dextrose particles, thereby producing a gritty, abrasive quality to the paste. Such abrasive qualities would not be desirable for application to the penis. In addition, pastes leave an undesirable residue which increases exposure of the sexual partner to the paste and vasodilatory substance.
  • Nitroglycerin is also available in an ointment (NITRO-BID® Marion Merrell Dow Inc.), in a base of lactose containing 2% nitroglycerin, white petrolatum and lanolin.
  • Another nitroglycerin ointment is NITROL® (Savage Laboratories) also in a base of lactose containing 2% nitroglycerin, white petrolatum and lanolin.
  • NITROL® Savage Laboratories
  • These ointments contain a petrolatum base which leaves a residue on the skin and must be removed.
  • compositions which may be used to stimulate blood flow to the external genitaha of females in order to increase sexual arousal and the potential for orgasm.
  • Topical application of such a composition to the external genitalia would facilitate the potential for sexual arousal and subsequent orgasm by increasing blood flow to the perineum, including the labia minora, clitoris, and vestibule of the vagina.
  • Peripheral vascular disease and other problems associated with peripheral blood vessels that result in vascular insufficiency may be caused by numerous factors. Some of these causes include, but are not limited to the following; diabetes, vitamin deficiency, disorders of the autonomic nervous system, smoking, drugs, especially vasoconstricting drugs, nicotine, low temperature, alcoholism, acute ischemia, atherosclerosis, phlebitis, thrombophlebitis, cardiac malfunction, trauma, obesity, Raynaud's disease, thromboangiitis obliterans (Buerger's disease) and others. Peripheral vascular disease and other problems associated with peripheral blood vessels that result in vascular insufficiency cause difficulty in visualizing blood vessels.
  • peripheral blood vessels The ability to see peripheral blood vessels is needed for several reasons, including but not limited to the following: insertion of needles; insertion of catheters, such as intraarterial and intravenous catheters for removal of blood, for administration of nutrients, fluids, blood or components of blood, electrolytes and pharmaceutical compositions; for insertion of angioplasty devices, stents, intravenous feeding tubes, intravenous and intraarterial probes for measurement of blood pressure and blood gases; and probes for visualization of arteries and veins in angiographic procedures.
  • vasodilatory composition that is convenient to use topically and is effective for rapidly increasing blood flow.
  • a topical vasodilatory composition that is easy to apply, is rapidly absorbed, and does not leave a residue like creams, pastes and ointments.
  • a topical vasodilatory composition for stimulating blood flow to the external genitalia of humans and animals.
  • a method for making this topical vasodilatory composition is also needed.
  • a method for using this topical vasodilatory composition for treatment of vascular insufficiency, impotence, and problems associated with sexual arousal and orgasm in animals and humans.
  • the present invention solves the problems described above by providing a composition comprising a vasodilatory gel useful for topical application to stimulate blood flow, a method for making the vasodilatory gel, and a method for using the vasodilatory gel.
  • the present invention also provides a method for making the vasodilatory gel of the present invention, including a vasodilatory gel containing nitroglycerin.
  • the present invention provides a method for rapidly stimulating blood flow by topically applying the vasodilatory gel of the present invention. Specifically, the present invention provides a method for treating vascular insufficiency through topical application of the vasodilatory gel.
  • the present invention involves topical application of the vasodilatory gel.
  • the vasodilatory gel of the present invention may be used for the treatment of vascular insufficiency associated with conditions including, but not limited to the following: impotence; problems with sexual arousal; anorgasmia; frostbite; diabetes; vitamin deficiency; disorders of the autonomic nervous system; smoking; drugs, especially vasoconstricting drugs; nicotine; low temperature; alcoholism; acute ischemia; atherosclerosis; phlebitis; thrombophlebitis; cardiac malfunction; trauma; obesity; Raynaud's disease; thromboangiitis obliterans (Buerger's disease); and stimulation of wound healing such as ulcer wounds by increasing blood flow; by topically applying the gel to an affected area of the skin. It is to be understood that the vasodilatory gel of the present invention may be topically applied to humans and animals who do not exhibit vascular insufficiency, as well as to humans and animals who do exhibit vascular insufficiency.
  • the vasodilatory gel of the present invention may also be topically applied to enlarge blood vessels for a variety of purposes, including but not limited to, obtaining blood samples, introducing substances such as drugs, nutrients, and electrolytes into the bloodstream, inserting an intraarterial or intravenous catheter, inserting stents, inserting needles, inserting angioplasty devices, inserting devices for use in imaging of vessels and other organs, such as introduction of dyes, contrast media, or labeled compositions including radiolabeled compositions, inserting probes for radiographic visualization and localization, and inserting devices which monitor blood pressure, blood chemistry, hematocrit and blood gas content.
  • the vasodilatory gel composition of the present invention is very effectively absorbed into the skin.
  • vasodilatory composition does not leave a residue on the skin, thereby avoiding problems associated with the use of creams, ointments, pastes, and other compositions found in the prior art.
  • an object of the present invention is to provide a vasodilatory gel which can be topically applied to increase blood flow.
  • Another object of the present invention is to provide a method for making this topical vasodilatory gel.
  • Yet another object of the present invention is to provide a method for using the vasodilatory gel to treat vascular insufficiency.
  • Still another object of the present invention is to provide a method for using the vasodilatory gel to increase blood flow.
  • a feature of the present invention is that topical application of the vasodilatory gel of the present invention rapidly increases vascular flow and facilitates visualization of blood vessels and access to blood vessels.
  • An advantage of the present invention is that topical vasodilation of the vasodilatory gel of the present invention facilitates access of health care professionals and veterinarians to the vascular system.
  • a further specific object of the present invention is to provide a topical vasodilatory gel which effectively increases vascular flow to the penis, thereby causing erections.
  • Another specific object of the present invention is to provide a method for using this topical vasodilatory gel for treating impotence.
  • Another advantage of the present invention is that topical application of the vasodilatory gel of the present invention to the penis of humans and animals, stimulates blood flow and causes erections, and is therefore useful for the treatment of impotence.
  • Another specific object of the present invention is to provide a method for using this topical vasodilatory gel for increasing vascular flow to the female external genitalia, thereby facilitating sexual arousal and the potential for attainment of orgasm.
  • Yet another specific object of the present invention is to provide a method for using this topical vasodilatory gel for treating anorgasmia.
  • vasodilatory gel of the present invention topical application of the vasodilatory gel of the present invention to the external genitalia of female humans and animals stimulates blood flow to the erectile tissues, causes clitoral erections, facilitates sexual arousal and is therefore useful for the treatment of anorgasmia.
  • An advantage of the present invention is that the vasodilatory substance is rapidly and efficiently absorbed into the skin from the topical vasodilatory gel leaving little or no residual gel on the skin.
  • a specific object of the present invention is to provide compositions comprising topical vasodilatory gels containing nitroglycerin, alone, or on combination with one or more additional vasodilatory substances, and a method for making these compositions.
  • FIGURE 1 is a graph comparing the average cumulative permeation of
  • the present invention provides a composition comprising a vasodilatory gel useful for topical administration of vasodilatory substances, a method for making this composition, and a method for using this composition.
  • the vasodilatory substance contains nitroglycerin.
  • the topical nitroglycerin gel composition preferably exhibits favorable penetration properties resulting in favorable cutaneous absorption of the active ingredient and leaves little or no gel residue on the skin.
  • Application of the nitroglycerin gel composition may be useful for treating a variety of conditions related to vascular insufficiency wherein increased vascular flow is desired, such as poor cutaneous vascular flow, impotence, and anorgasmia.
  • impotence is used herein to mean an inability to achieve or sustain an erection of the penis.
  • vasoactive substance such as vasoactive intestinal polypeptide, calcitonin gene- related peptide, neuropeptide Y, atrial natriuretic peptide, endothelin, and analogs and fragments thereof, including receptor agonists and antagonists.
  • Vasodilatory substances include substances which stimulate nitric oxide synthase, the enzyme responsible for nitric oxide production.
  • Vasodilatory substances also include catecholaminergic agents, including but not limited to norepinephrine, epinephrine, dopamine, alpha adrenergic agents and beta adrenergic agents and analogs thereof.
  • Alpha adrenergic antagonists include, but are not limited to, phentolamine and yohimbine and analogs thereof.
  • Beta adrenergic antagonists include, but are not limited to, propranolol, timolol, metroprolol, and atenolol and analogs thereof.
  • Other vasodilatory substances include prostaglandins, including but not limited to prostaglandin E (PGE) and analogs thereof.
  • Vasodilatory substances also include papaverine, ergot derivatives, nicotinic acid, and nicotinyl alcohol, and analogs thereof.
  • Vasodilatory substances also include substances referred to by those skilled in the art as nitric oxide generators which produce nitric oxide, stimulate production of nitric oxide or mimic the effect of nitric oxide generators, and analogs thereof.
  • a preferred vasodilatory substance is nitroglycerin.
  • nitric oxide generators means molecules which produce nitric oxide, stimulate production of nitric oxide or mimic the effect of nitric oxide generators.
  • Such stimulation of nitric oxide production includes stimulators of the enzyme nitric oxide synthase, and nitric oxide donors.
  • Such compounds include, but are not limited to, nitroglycerin (glyceryl trinitrate), nitroprusside, amyl nitrite, sodium nitrite, pentaerythritol tetranitrate, isosorbide dinitrate, mannitol hexanitrate, and triethanolamine trinitrate biphosphate, L-arginine (free base), and dephostatin (diethylamine NONOate) and analogs thereof.
  • vasodilatory gel is used herein to mean a composition which is rapidly absorbed through the skin and leaves little or no oily or greasy residue.
  • topical application is employed to mean application of the vasodilatory compositions of the present invention to the skin. Topical application may be accomplished through means known to one of ordinary skill in the art. Such means include but are not limited to the following: manual application through the use of a gloved or non-gloved hand; application through the use of swabs, wipes, pads, bandages, and sticks; and spray application.
  • the vasodilatory gel of the present invention may also be applied topically through application to the penis of a condom containing the vasodilatory gel.
  • animal is used herein to mean humans and non-human animals of both sexes.
  • the present invention also includes the combination of multiple vasodilatory substances into the vasodilatory gel composition.
  • a nitric oxide generator may be combined with one or more additional vasodilatory substances in the vasodilatory gel composition.
  • nitroglycerin may be combined with other vasodilatory substances in the vasodilatory gel composition.
  • vasodilatory composition of the present invention may be used in other forms such as sticks, sprays, liquids, creams, and ointments.
  • Vasodilatory Gel Composition
  • the vasodilatory gel composition described herein contains one or more vasodilatory substances, a polymer, a penetrant or solvent, and a neutralizing agent.
  • the gel contains about 0.5% to 20%, more preferably 1% to 10%, and most preferably 1.5% to 4% (weight/weight) of the vasodilatory substance. Unless otherwise indicated, expressions of percentages are on a weight/weight basis throughout the present application.
  • the gel contains about 0.15% to 15%, more preferably 0.5% to 10%, and most preferably 1% to 5% of the polymer.
  • the gel contains about 75% to 99%, more preferably 80% to 97%, and most preferably 90% to 96% of the solvent or penetrant.
  • the gel contains about 0.01% to 0.5%, more preferably 0.05% to 0.4%, and most preferably 0.1 % to 0.3% of the neutralizing agent.
  • the vasodilatory substance is combined with an acrylic polymer, preferably carboxy polymethylene, a solvent or penetrant, preferably propylene glycol, and a neutralizing agent.
  • Neutralizing agents include, but are not limited to tris (hydroxymethyl) aminomethane, sodium hydroxide (NaOH), and sodium phosphate, including monobasic, dibasic and tribasic forms of sodium phosphate.
  • a preferred neutralizing agent is tris (hydroxymethyl) aminomethane.
  • a preferred embodiment is a vasodilatory gel composition
  • a vasodilatory gel composition comprising about 0.5% to 20% of nitroglycerin, 75% to 99% propylene glycol, 0.15% to 15% carboxy polymethylene, and about 0.01% to 0.5% of tris (hydroxymethyl) aminomethane. More preferred is a vasodilatory gel composition comprising a gel containing about 1% to 10% of nitroglycerin, about 80% to 97% of propylene glycol, about 0.5% to 10% of carboxy polymethylene and about 0.05% to 0.4% of tris (hydroxymethyl) aminomethane.
  • vasodilatory gel composition comprising a gel containing about 1.5% to 4% of nitroglycerin, about 90% to 96% of propylene glycol, about 1% to 5% of carboxy polymethylene, and about 0.1% to 0.3% of tris (hydroxymethyl) aminomethane. These compositions are all compatible with topical application.
  • vasodilatory composition preservatives, antiseptics, bacteriostats, anti-viral compounds, contraceptives, stabilizers and antioxidants well known to those of ordinary skill in the art can be used in the vasodilatory composition.
  • compositions and agents known by one of ordinary skill in the art to be useful in preventing sexually transmitted disease or other infectious diseases, including blood borne infectious diseases may be combined with the vasodilatory composition of the present invention.
  • vasodilatory composition various anti-fungals, anti- microbials, antiseptics, anesthetics, analgesics, tactile sensitizers, moisturizers, lubricants, colors, flavors, fragrances and assorted scents known to one of skill in the art may be added to the vasodilatory composition.
  • the vasodilatory gel is produced in the following manner.
  • the vasodilatory substance is dissolved in an appropriate solvent.
  • the preferred solvent is propylene glycol. It is to be understood that different vasodilatory substances require different solvation conditions. One of skill in the art would be able to determine which solvent or solvents are useful for solubilizing different vasodilatory substances. Accordingly, other solvents and penetrants besides propylene glycol may be employed. It is to be understood that some chemicals, such as propylene glycol, act as both a solvent and penetrant.
  • the vasodilatory substance is the nitric oxide generator nitroglycerin in powdered form.
  • This nitroglycerin powder is added to the solvent and penetrant, propylene glycol, with slow sifting, such that the powder is sprinkled as discrete particles into a vortex of propylene glycol created by a mixer.
  • the concentration of nitroglycerin is an amount of about 1 % to 30% of nitroglycerin to propylene glycol.
  • Stirring or mixing is done in a manner to avoid entrapment of air bubbles by adjusting the stirring or mixing speed. This step may be performed at room temperature although temperatures of from approximately 13° C to 33° C may be employed.
  • the mixer is a vertical shaft mixer operating at less than about 500 rpm to create a vortex, although other mixers and stirrers may be employed.
  • the mixing is sufficient to thoroughly dissolve the nitroglycerin in propylene glycol.
  • a preferred mixture of nitroglycerin in propylene glycol is about 1% to 20%.
  • a more preferred mixture of nitroglycerin in propylene glycol is about 3% to 15%.
  • Another more preferred mixture of nitroglycerin in propylene glycol is about 4% to 12%.
  • a polymer such as an acrylic polymer
  • penetrant such as propylene glycol
  • Aery He polymers which may be used in the practice of the present invention include, but are not hrnited to carboxy polymethylene.
  • Carboxy polymethylene is also known CARBOPOL® and carbomer, and is manufactured by B. F. Goodrich Specialty Chemicals.
  • Acceptable carboxy polymethylene for use in the present invention includes, but is not limited to carboxy polymethylene known as CARBOPOL® 934P NF, CARBOPOL® 974P NF, and CARBOPOL® 980 NF.
  • the amount of acrylic polymer as a percent of the total weight of the vasodilatory composition is about 0.15% to 15%, preferably 0.5% to 10%, more preferably from 1.0% to 5%.
  • carboxy polymethylene is used as the acrylic polymer at a final concentration of 1.5%. Stirring and mixing are performed in a manner to avoid formation or entrapment of air bubbles. This step is performed at room temperature although temperatures of from approximately 13° C to 33° C may be employed. After initial dissolution of carboxy polymethylene in a small amount of propylene glycol, the carboxy polymethylene is added to the vortex of the mixture of nitroglycerin in propylene glycol created by a mixer.
  • the mixer is a vertical shaft mixer operating at less than about 500 rpm to create a vortex, although other mixers, such as impeller mixers and stirrers may be employed.
  • the mixing is sufficient to thoroughly mix the carboxy polymethylene in the nitroglycerin/propylene glycol mixture. Any air bubbles present at this time are removed by reducing the speed of the mixer.
  • Neutralizing agents are initially dissolved in a solvent, such as propylene glycol, by heating the mixture at a temperature below approximately 60° C. Temperatures ranging from about 35° C to 60° C, preferably 40° C to 58° C, most preferably 40° C to 50° C, may be used for dissolving the neutralizing agent in the solvent.
  • Neutralizing agents useful in the practice of the present invention include, but are not limited to tris (hydroxymethyl) aminomethane, sodium phosphate and NaOH. Tribasic sodium phosphate is a preferred form of sodium phosphate. It is to be understood that other neutraUzing agents and bases may be employed and are encompassed within the scope of the present invention. Neutralizing agents are dissolved in a container separate from the container with the vasodilatory substance.
  • the final concentration of a neutralizing agent, such as tris (hydroxymethyl) aminomethane, in the vasodilatory composition is about 0.01% to 0.5%.
  • a more preferred concentration is about 0.05% to 0.4% of tris (hydroxymethyl) aminomethane.
  • a most preferred concentration of tris (hydroxymethyl) aminomethane is about 0.1% to 0.3%.
  • the solution of neutralizing agent in propylene glycol is cooled to room temperature.
  • This cooling step may occur gradually at room temperature or may be accelerated through the use of water jacketed tanks or other means known to one of skill in the art.
  • air bubbles are removed from the dispersion.
  • the mixer speed is reduced and the neutralizing agent is added gradually to the mixture containing the vasodilatory substance and polymer, resulting in gel formation.
  • gel formation may begin at a pH of approximately 6, the neutralizing agent is added until a pH of approximately 7.2 is obtained so that topical application of the gel occurs at relatively neutral pH conditions.
  • the vasodilatory gel composition of the present invention is topically applied to the skin in amounts such that at least about 2 mg of active vasodilatory substance or substances is applied.
  • Various means may be used for application such as pads, wipes, tubes, cotton swabs, plastic or wooden applicators, aerosols such as sprays, applicator cans or bottles, gauze, gloved hand, digital glove and condom.
  • the vasodilatory gel composition is applied as one would apply a lubricant to the penile skin on the shaft and/or on the glans.
  • Topical application of the vasodilatory gel composition of the present invention to the penis for the treatment of impotence can be used to enhance fertility by producing erections of sufficient strength and duration to achieve vaginal penetration and ejaculation.
  • Topical application of the vasodilatory gel facilitates sexual arousal and increases the chances for attainment of orgasm and ejeculation.
  • a condom containing the vasodilatory gel may be worn throughout intercourse.
  • Topical application of the vasodilatory gel composition of the present invention to external genitalia of women increases blood flow, facilitates sexual arousal and increases the chances for attainment of orgasm. Accordingly, this topical application may be used as a treatment for anorgasmia. Since topical application of the vasodilatory gel composition facilitates sexual arousal, it may be used to increase the opportunity for sexual intercourse and increase sexual satisfaction. Another potential benefit of topically applying the vasodilatory gel composition is that fertility may be enhanced by increasing the frequency of heterosexual intercourse.
  • vasodilatory gel is rapidly absorbed and leaves little or no residue. Soon after application, blood flow increases.
  • the vasodilatory gel composition of the present invention may be topically applied to the penis to stimulate blood flow and produce erections in individuals who are not impotent.
  • the vasodilatory gel composition of the present invention may be topically applied to the external genitalia of females to stimulate blood flow in individuals who have no difficulty in becoming sexually aroused or attaining orgasm.
  • An important aspect of the present invention is that topical application of the vasodilatory composition increases blood flow.
  • An advantage of the present invention is that the vasodilatory composition is rapidly and efficiently absorbed thereby transporting the vasodilatory substance into and across the skin.
  • An additional advantage is that little or no residue remains after the vasodilatory gel is absorbed into the skin.
  • An advantage of the present invention is that topical application to the skin increases vascular diameter and enables visualization of blood vessels for insertion of a variety of devices, including but not limited to needles, shunts, catheters, and probes to measure blood pressure and blood oxygenation.
  • Desirable locations for topical application of the vasodilatory composition of the present invention for the purpose of dilating vessels include, but are not limited to the following: the upper extremity, including the dorsum of the hand, the wrist, forearm, antecubital fossa and arm; the neck; the lower extremity, including the foot, ankle, leg, popliteal fossa, thigh; the torso, the scalp and other sites known to one of ordinary skill in the art.
  • vasodilatory gel of the present invention may be topically applied in order to stimulate blood flow through dilation of vessels in humans and animals who do not exhibit vascular insufficiency, as well as those who do exhibit some vascular insufficiency.
  • NVG nitroglycerin
  • Nitroglycerin was added at room temperature to propylene glycol with slow sifting, such that the nitroglycerin was sprinkled as discrete particles into a vortex of propylene glycol created by a mixer.
  • the concentration of nitroglycerin was about 10% of nitroglycerin to propylene glycol (weight/weight%).
  • Stirring or mixing was done in a manner to avoid entrapment of air bubbles by adjusting the stirring or mixing speed.
  • the mixer was a vertical shaft mixer operating at less than 500 rpm to create a vortex. The mixing was sufficient to thoroughly dissolve the nitroglycerin in propylene glycol. Samples of the mixture were obtained from different location in the vortex to examine the degree of solvation.
  • the mixer used was a vertical shaft mixer operating at less than 500 rpm to create a vortex.
  • the mixing was sufficient to thoroughly mix the carboxy polymethylene in the nitroglycerin/propylene glycol mixture. Any air bubbles present at this time were removed by reducing the speed of the mixer.
  • the neutralizing agent used was a 0.5 M solution of tris (hydroxymethyl) aminomethane (ANGUS Chemical Company, Buffalo Grove, IL) in propylene glycol.
  • the tris (hydroxymethyl) aminomethane solution was prepared in a separate container from the vessel containing the nitroglycerin/propylene glycol mixture.
  • This tris (hydroxymethyl) aminomethane solution was prepared by adding tris amino (0.092 kg) to propylene glycol (1.428 kg) and heating this mixture at 55° C to 60° C with constant stirring until the tris (hydroxymethyl) aminomethane completely dissolved in the propylene glycol.
  • the solution of tris (hydroxymethyl) aminomethane was permitted to return to room temperature before adding it to the mixture containing the nitroglycerin, propylene glycol, and carboxy polymethylene. After ensuring that there were no air bubbles in the mixture, the speed of the mixer was reduced such that no vortex was created. Next the tris (hydroxymethyl) aminomethane neutralizing agent (1.52 kg) was added resulting in gel formation and a sudden increase in the viscosity. At this point the mixing speed was optionally increased to ensure neutralization of the entire mixture but without entrapping air or creating a vortex. A colorless to translucent gel was formed. Neutralization started to occur at a pH of about 6, and so no more than the mentioned amount of neutralizing agent was added even if the final pH was not 7.4.
  • the epidermis was placed on a piece of parafilm and 75 mg of either Formulation E gel or Fougera ointment was placed on its center.
  • the piece of epidermis was then mounted on the vertical diffusion cells after the receptor compartment was filled with 5.0 ml of 20% propylene glycol in saline.
  • the gel or ointment was spread with a spatula so that it covered the entire area enclosed by the donor compartment. Next, the donor cell was clamped into place. Samples were taken at various time intervals and the nitroglycerin content determined using a method described below. The results of the permeation experiments are presented in Figure 1 and are plotted as the cumulative amount of drug permeated as a function of time. Samples were replaced with 20% propylene glycol in saline and this was taken into consideration in the calculations.
  • the mobile phase was a combination of methanol and water (50:50) and the flow rate was 1 ml/minute. Absorbance was monitored in a spectrophotometer at 220 nm. The retention time of nitroglycerin was approximately 9 minutes. A standard curve was made by injecting different amounts of a standard solution of nitroglycerin into the HPLC and analyzing peak height and area under the curve for subsequent calculations of the nitroglycerin content of transported samples.
  • penile tumescence increases and an erection is achieved.
  • the erection persists for a period of about 9.5 to 20 minutes. No residual gel remains on the penis after application, indicating rapid and thorough abso ⁇ tion into the skin.
  • a female with peripheral vascular insufficiency secondary to diabetes topically applies the vasodilatory gel composition containing nitroglycerin to the skin of the foot.
  • the amount of vasodilatory gel was sufficient to contain at least 2 mg of nitroglycerin.
  • she notices increased vasodilation in cutaneous vessels.
  • the vasodilation is accompanied by a sensation of warmth in the foot.
  • a male with peripheral veins that can not be visualized in the antecubital fossa and the ventral surface of the wrist requires insertion of a vascular line and withdrawal of a blood sample.
  • a health care worker applies the vasodilatory gel composition containing nitroglycerin to the skin of the antecubital fossa and/or the ventral surface of the wrist.
  • the amount of vasodilatory gel was sufficient to contain at least 2 mg of nitroglycerin.
  • increased vasodilation in cutaneous vessels renders visible the veins and arteries in these regions.
  • the vasodilation is sufficient to enable the health care worker to insert a needle into the vein to obtain a blood sample and also to insert a catheter.
  • An elderly, overweight male with peripheral veins in the upper and lower extremities that can not be visualized is admitted to the emergency room in a state of shock and dehydration. Blood samples are needed to examine blood chemistry. Rapid insertion of intravenous lines for administration of fluids and electrolytes is desired by the health care professionals. Rapid insertion of an intraarterial radial line is desired by the health care professionals for evaluation of pulse pressures and blood gases.
  • vasodilatory gel containing nitroglycerin to the antecubital fossa, the ventral surface of the wrist and to the ankle.
  • the amount of vasodilatory gel is sufficient to contain at least 2 mg, preferably 5 mg, of nitroglycerin at each site of application.
  • the blood vessels in these regions dilate soon after application of the vasodilatory gel.
  • the health care professionals then insert intravenous lines in the antecubital fossa and in the veins of the ankle, and an intraarterial line in the radial artery.
  • vasodilatory gel composition containing nitroglycerin to her external genitalia, specifically to the labia majora, labia minora and clitoris.
  • the amount of vasodilatory gel was sufficient to contain at least 2 mg of nitroglycerin.
  • she notices an increased sensation of warmth in her external genitalia secondary to increased vascular flow. These sensations are accompanied by increased sexual arousal.
  • vasodilatory gel composition containing nitroglycerin to her external genitalia, specifically to her labia majora, labia minora and clitoris.
  • the amount of vasodilatory gel was sufficient to contain at least 2 mg of nitroglycerin.
  • she notices an increased sensation of warmth in her external genitalia secondary to increased vascular flow. These sensations are accompanied by increased sexual arousal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une nouvelle composition comprenant un gel de vasodilatation s'utilisant en application topique pour la stimulation du flux sanguin, pour la visualisation des vaisseaux sanguins, pour le traitement de l'anorgasmie et pour le traitement de l'impuissance et d'autres formes d'insuffisance vasculaire; l'invention concerne également une méthode de préparation de ce gel de vasodilatation et une méthode d'utilisation de cette composition pour stimuler le flux sanguin, pour visualiser les vaisseaux sanguins, pour traiter l'anorgasmie et pour traiter l'impuissance et d'autres formes d'insuffisance vasculaire. La substance de vasodilatation préférée dans le gel de vasodilatation est la nitroglycérine.
PCT/US1999/001830 1998-01-28 1999-01-28 Composition de gel de vasodilatation topique et ses methodes d'utilisation et de production WO1999038472A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24790/99A AU2479099A (en) 1998-01-28 1999-01-28 Topical vasodilatory gel composition and methods of use and production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7290498P 1998-01-28 1998-01-28
US60/072,904980128 1998-01-28

Publications (2)

Publication Number Publication Date
WO1999038472A2 true WO1999038472A2 (fr) 1999-08-05
WO1999038472A3 WO1999038472A3 (fr) 2000-01-20

Family

ID=22110459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001830 WO1999038472A2 (fr) 1998-01-28 1999-01-28 Composition de gel de vasodilatation topique et ses methodes d'utilisation et de production

Country Status (2)

Country Link
AU (1) AU2479099A (fr)
WO (1) WO1999038472A2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
WO2002015913A1 (fr) * 2000-08-23 2002-02-28 Phairson Medical, Inc. Traitements de traumas et autres indications
EP1222913A4 (fr) * 1999-10-21 2003-06-25 Kao Corp Epilatoires et agents pour usage externe
US6872384B1 (en) 1998-02-23 2005-03-29 Life Medical Sciences, Inc. Treatment of trauma
EP2027859A1 (fr) * 2007-08-21 2009-02-25 Mcneil-PPC, Inc Compositions anhydres pour augmenter la circulation sanguine
EP2027857A2 (fr) * 2007-08-21 2009-02-25 Mcneil-PPC, Inc Compositions anhydres utiles pour atteindre un bien-être sexuel amélioré
EP2027858A1 (fr) * 2007-08-21 2009-02-25 Mcneil-PPC, Inc Procédé pour atteindre un bien-être sexuel amélioré à l'aide de compositions anhydres
WO2009112258A1 (fr) * 2008-03-14 2009-09-17 G. Pohl-Boskamp Gmbh & Co. Kg Préparation pharmaceutique à grande stabilité, contenant le principe actif trinitrate de glycérol
US7872049B2 (en) * 2008-03-14 2011-01-18 G. Pohl-Boskamp Gmbh & Co. Kg Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US9101592B2 (en) 2011-02-25 2015-08-11 G. Pohl-Boskamp Gmbh & Co. Kg Stabilized granules containing glyceryl trinitrate
US9180109B2 (en) 2010-08-03 2015-11-10 G. Pohl-Boskamp Gmbh & Co. Kg Use of glyceryl trinitrate for treating traumatic edema
US9248099B2 (en) 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
US9675637B2 (en) 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US10034850B2 (en) 2013-11-29 2018-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Sprayable aqueous composition comprising glyceryl trinitrate
US11166931B2 (en) 2012-05-31 2021-11-09 G. Pohl-Boskamp Gmbh & Co. Kg Induction of arteriogenesis with an NO (nitric oxide) donor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5467022A (en) * 1977-11-07 1979-05-30 Toko Yakuhin Kogyo Kk Topical agent and production thereof
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5571794A (en) * 1995-06-22 1996-11-05 Frome; Bruce M. Non-invasive novel method fo cosmetic lip augmentation

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6872384B1 (en) 1998-02-23 2005-03-29 Life Medical Sciences, Inc. Treatment of trauma
US6514536B2 (en) 1998-09-08 2003-02-04 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US7468421B2 (en) 1999-10-21 2008-12-23 Kao Corporation Depilatories and agents for external use
EP1222913A4 (fr) * 1999-10-21 2003-06-25 Kao Corp Epilatoires et agents pour usage externe
US6884772B1 (en) 1999-10-21 2005-04-26 Kao Corporation Depilatories and agents for external use
WO2002015913A1 (fr) * 2000-08-23 2002-02-28 Phairson Medical, Inc. Traitements de traumas et autres indications
US9700578B2 (en) 2003-07-09 2017-07-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9675637B2 (en) 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP2027859A1 (fr) * 2007-08-21 2009-02-25 Mcneil-PPC, Inc Compositions anhydres pour augmenter la circulation sanguine
EP2027857A2 (fr) * 2007-08-21 2009-02-25 Mcneil-PPC, Inc Compositions anhydres utiles pour atteindre un bien-être sexuel amélioré
EP2027858A1 (fr) * 2007-08-21 2009-02-25 Mcneil-PPC, Inc Procédé pour atteindre un bien-être sexuel amélioré à l'aide de compositions anhydres
EP2444089A3 (fr) * 2007-08-21 2012-08-29 McNeil-PPC, Inc. Compositions anhydres utiles pour atteindre un bien-être sexuel amélioré
US20110240508A1 (en) * 2008-03-14 2011-10-06 G. Pohl-Boskamp Gmbh & Co. Kg Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate
AU2009224968B2 (en) * 2008-03-14 2014-01-16 G. Pohl-Boskamp Gmbh & Co. Kg Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
US7872049B2 (en) * 2008-03-14 2011-01-18 G. Pohl-Boskamp Gmbh & Co. Kg Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate
WO2009112258A1 (fr) * 2008-03-14 2009-09-17 G. Pohl-Boskamp Gmbh & Co. Kg Préparation pharmaceutique à grande stabilité, contenant le principe actif trinitrate de glycérol
US9180109B2 (en) 2010-08-03 2015-11-10 G. Pohl-Boskamp Gmbh & Co. Kg Use of glyceryl trinitrate for treating traumatic edema
US9693983B2 (en) 2010-08-03 2017-07-04 G. Pohl-Boskamp Gmbh & Co. Kg Use of glyceryl trinitrate for treating traumatic edema
US9101592B2 (en) 2011-02-25 2015-08-11 G. Pohl-Boskamp Gmbh & Co. Kg Stabilized granules containing glyceryl trinitrate
US9616023B2 (en) 2011-02-25 2017-04-11 G. Pohl-Boskamp Gmbh & Co. Kg Stabilized granules containing glyceryl trinitrate
US9248099B2 (en) 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
US9675552B2 (en) 2012-05-31 2017-06-13 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
US11166931B2 (en) 2012-05-31 2021-11-09 G. Pohl-Boskamp Gmbh & Co. Kg Induction of arteriogenesis with an NO (nitric oxide) donor
US10034850B2 (en) 2013-11-29 2018-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Sprayable aqueous composition comprising glyceryl trinitrate
US10987332B2 (en) 2013-11-29 2021-04-27 G. Pohl-Boskamp Gmbh & Co. Kg Sprayable aqueous composition comprising glyceryl trinitrate

Also Published As

Publication number Publication date
AU2479099A (en) 1999-08-16
WO1999038472A3 (fr) 2000-01-20

Similar Documents

Publication Publication Date Title
JP3866906B2 (ja) 肛門疾患を治療するｎｏ供与体及び方法
CN1139380C (zh) 含硝酸甘油的水基外用乳膏及其制备方法和应用
US4439432A (en) Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
KR100660239B1 (ko) 여성 성기능 장애를 개선시키기 위한 조성물 및 방법
WO1999038472A2 (fr) Composition de gel de vasodilatation topique et ses methodes d'utilisation et de production
US6056966A (en) Method and compositions for treating impotence
EP0266968A2 (fr) Onguent gélifié contenant un agent vasodilatateur
Johansson et al. The effect of progestin R 2323 released from vaginal rings on ovarian function
WO2017143119A1 (fr) Traitement topique de l'anorgasmie
US20020187165A1 (en) Composition for female sexual arousal
US20040038984A1 (en) Composition for male & female sexual arousal
RU2310455C2 (ru) Состав для лечения геморроев
CA2214418C (fr) Creme pour application locale a base d'eau contenant de la nitroglycerine, et son procede de preparation et d'utilisation
WO2006061689A1 (fr) Systeme d'administration de medicaments topiques
WO2000010559A1 (fr) Traitement de l'inorgasmie
JP2005220052A (ja) 性機能障害治療用外用剤
MXPA96000386A (en) Nitric oxide donating composition and method for the treatment of ana disorders
EA004716B1 (ru) Ректальные и вагинальные суппозитории
MXPA00011316A (es) Composiciones que contienen mono o dinitrato organico para el tratamiento de la impotencia
MXPA00011386A (en) A medicament for prevention and treatment of sexual dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载